Spectographic metabolite-signature for identifying a subject's susceptibility to drugs
US11366102B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2019 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Jan 13, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.